TGV Therapeutics, the pharmaceutical company developing first-in-class drugs for fighting antibiotic-resistant infections, announced it is working with the National Institutes of Health to expand its research on a drug that shows promise against new fungal superbugs.


TGV Therapeutics and its advisors, Dr. George and Victor Tetz, said initial data indicate their drug candidate, MYC-053, is effective against numerous emerging multidrug-resistant invasive fungal pathogens, including recent emerging threat –  Candida auris, which appears to spread in healthcare facilities.

The overall crude in-hospital mortality rate of C.auris candidemia ranges from 30% to 60%, and today it is one of the deadliest fungi. Anne Schuchat, former acting director of the CDC, has termed it a “catastrophic threat.”

MYC-053 is a structurally distinct both oral and IV antifungal antibiotic with a unique dual mode of action that shows promise in fighting a number of pathogenic fungi.  After reviewing TGV’s application to conduct studies, the NIH connected the company with the number of research centers for expanded in-depth research.

“We are pleased that the NIH recognizes the potential of MYC-053 and the urgent need for expanded research and development of this groundbreaking drug,” said Haran Schlamm, a member of scientific advisory board. “As we have seen with antibiotics, some strains of fungus are becoming increasingly resistant to the antifungal agents.  And it is crucial we speed up research and testing of this drug to fight existing emerging multidrug-resistant species, as well as to avoid the spread of another dangerous fungi.”